In a recent study published in Biomaterials, a team of researchers led by Hesperos Chief Scientist Dr. J. Hickman established a significant finding to better understand ALS etiology and potential new treatment targets.
Read the Open Letter here We are proud to support this open letter to congress encouraging representatives to pass the FDA Modernization Act. Originally passed in 1938, the Federal Food, Drug, and Cosmetics Act (FFDCA) was … Read More
Financial Times wrote an excellent feature on microphysiological systems, highlighting Hesperos’ Human-on-a-Chip.
Hesperos, Inc. appoints new Chief Executive Officer, Dr. James Kronauge I’m excited to join Hesperos as we expand the capabilities of the Human-on-Chip platform enabling drug developers unprecedented insight into specific disease states, especially for rare … Read More
1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.
2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.
Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More
Hesperos and Tabula Rasa receive $1.9M National Institutes of Health Research Grant Focused on Preventable Drug-Induced Alzheimer’s Disease